$2.5 billion in revenue. A 16% collapse in dermatology. An 11% plunge in U.S. companion animal sales. And a CEO who admits the competitive landscape has fundamentally shifted.
Zoetis reported second-quarter 2026 results on 6 August, and the headline numbers tell a story the animal-health industry has been dreading. Organic revenue declined 1% to $2.5 billion. Global companion animal revenue fell 6% on an organic operational basis. The company's flagship dermatology franchise, built on Apoquel and Cytopoint, shrank 16% worldwide and 18% in the United States. In response, Zoetis slashed its full-year guidance and warned that market stabilization could take up to 18 months.
The Numbers Behind the Reset
Zoetis broke the quarter down into stark regional and segment contrasts:
Metric | Q2 2026 | Year-over-Year Organic Change |
Global revenue | $2.5B | -1% |
U.S. revenue | $1.3B | -7% |
International revenue | $1.2B | +6% |
Companion animal | $1.7B | -6% |
Key dermatology | $395M | -16% |
Simparica franchise | $442M | Flat |
OA pain monoclonal antibodies | $147M | -3% |
Livestock | $731M | +11% |
Adjusted net income | $781M | -2% |
Adjusted diluted EPS | $1.87 | +4% reported |
The earnings-per-share figure looks healthy only because Zoetis repurchased more than $550 million of its own shares during the quarter. Strip out the buyback effect, and the underlying profit trend is negative.
What Happened to Dermatology
Apoquel and Cytopoint built the modern veterinary dermatology market. For years, they enjoyed near-monopoly status in pruritus and atopic dermatitis management. That era is ending.
New competitors have entered the U.S. market with aggressive discounting, rebates, and cross-portfolio bundling. CEO Kristin Peck was direct: "The nature of competition has changed." She described rivals using "higher levels of discounting, rebates, cross-portfolio bundling, and other incentives to compete for existing patients."
The result is visible in market-share data. Zoetis's U.S. in-clinic dermatology share held at approximately 86% in Q2. That sounds dominant until you realise it represents a 5-percentage-point drop from the previous quarter and a 10-point decline year-over-year. In a category that Zoetis defined, the erosion is accelerating.
Peck insisted that Zoetis will not cut list prices. Instead, the company is deploying "targeted gross-to-net investments"—promotions, rebates, point-of-sale offers for pet owners, and cross-portfolio bundling of its own. The strategy sacrifices near-term net revenue to protect volume. CFO Wetteny Joseph acknowledged that these actions produce lower realised net prices, but argued they preserve long-term franchise value better than permanent structural cuts.
The question is how long Zoetis can absorb the margin compression. Peck estimated share stabilisation could take "six, 12, or 18 months." She also noted that a long-acting Cytopoint formulation, expected to receive approval later this year, could become a differentiated weapon in the fight.
Simparica and OA Pain: The Hidden Weakness
The Simparica franchise, which includes Simparica Trio, was flat globally at $442 million. A 19% international surge was completely wiped out by a 6% U.S. decline. In the U.S., Simparica Trio's in-clinic share remains dominant at roughly 21%, nearly double the nearest competitor. But the underlying visit trends are ugly: flea, tick, and heartworm visits were down 7%. Growth in retail channels, which had previously offset clinic softness, is no longer enough.
Osteoarthritis pain monoclonal antibodies fell 3% to $147 million. The headline masks a brutal internal split. U.S. canine OA pain mAbs collapsed 24% against a difficult year-ago comparison. Feline OA pain grew 12%, helped by early launches of Portela and continued Solensia adoption. International canine OA pain showed early contributions from Lenivia. The feline and international growth is promising, but the U.S. canine market is the revenue engine, and it is sputtering.
The Livestock and Diagnostics Bright Spots
Not everything at Zoetis is shrinking. Livestock revenue surged 11% organically to $731 million, driven by a 23% explosion in U.S. cattle demand. The growth was fuelled by elevated cattle demand linked to the New World screwworm outbreak, improved product supply, and favourable producer economics.
Joseph cautioned that the Q2 U.S. livestock number was partly transitory. Timing of supply and injectable parasiticide demand inflated the figure. Normalised U.S. livestock growth was in the high single digits, and full-year livestock growth is expected to settle in the mid-to-high single-digit range.
Companion animal diagnostics, a smaller business at $118 million, grew 12%. The drivers were continued adoption of Vetscan Imagyst and VetScan OptiCell, plus the acquisition of VitalRADS, which extends Zoetis into veterinary teleradiology. Peck highlighted diagnostics as a strategic priority because it strengthens daily clinic relevance and creates a stronger launch pathway for future therapeutics.
Guidance Slashed: What Management Now Expects
Zoetis lowered its full-year 2026 outlook significantly:
- Organic revenue: decline of 3% to 1% (previously growth)
- Reported revenue: $9.12 billion to $9.32 billion
- Adjusted net income: decline of 9% to 5%
- Adjusted diluted EPS: $6.15 to $6.25
The guidance includes $60 million to $65 million of incremental foreign-exchange headwinds and assumes that current competitive and macroeconomic pressures persist. Joseph disclosed that July sales trends have "not yet indicated market stabilization."
Analysts on the earnings call pressed for clarity on how long the promotional war would last. Peck's answer was telling: Zoetis is not assuming the market gets easier. The company is already cutting costs. Adjusted SG&A fell 4% operationally in Q2, with more benefits expected in the second half. R&D spending, however, rose 4%, signalling that Zoetis will not sacrifice its pipeline to protect short-term margins.
Leadership Changes and Strategic Shifts
The earnings day also brought organisational changes. Abhay Nayak, previously a leader in the diagnostics unit, was promoted to EVP and President of U.S. Commercial Operations in June. More significantly, Jay Zacara will join on 17 August as EVP, Chief Financial Officer and Chief Operating Officer—a newly created role combining finance, manufacturing, and supply-chain oversight. The stated goal is to "enable faster decision-making and greater connectivity." Outgoing CFO Wetteny Joseph will remain as a special advisor into early 2027.
The restructuring suggests that Zoetis recognises its problems are not merely commercial but operational. When competitors can undercut you on price while you defend premium positioning, speed of response matters.
What This Means for Veterinary Practices
For veterinarians, the Zoetis results create both opportunity and confusion.
Promotional pricing is now a tool, not an exception. Practices that have historically paid standard wholesale prices for Apoquel, Cytopoint, and Simparica Trio should expect to see rebates, bundled offers, and loyalty programmes. Negotiate actively. Zoetis is explicitly using gross-to-net incentives to retain volume, which means the listed price is no longer the real price.
Competitor alternatives are gaining shelf space. The 10-point year-over-year share loss in dermatology means that rival products are being prescribed, stocked, and trusted. Practices should review their formularies and understand the clinical and economic profiles of competing therapies, not just the Zoetis portfolio.
Diagnostics growth is strategic. Zoetis's 12% growth in companion animal diagnostics, while small in absolute dollars, indicates where the company is placing long-term bets. Practices that integrate Zoetis diagnostic platforms may find themselves at the front of the line for future therapeutic launches.
Livestock practices are in a seller's market. The 23% U.S. livestock surge reflects real demand. Cattle veterinarians and large-animal practices should expect strong product availability and potentially favourable terms from a Zoetis that needs livestock growth to offset companion animal weakness.
FAQ
Why is Zoetis losing share in dermatology?
New competitors have entered the U.S. market with lower prices, rebates, and bundling strategies. Pet owners are more value-conscious, and clinic visits are down. Zoetis's U.S. in-clinic dermatology share fell 10 percentage points year-over-year.
Will Zoetis cut list prices?
No. Management has committed to maintaining list prices and using temporary promotions, rebates, and point-of-sale offers instead. They argue this protects long-term brand value.
How long will the competitive pressure last?
CEO Kristin Peck estimated 6 to 18 months for share stabilisation. July trends showed no sign of stabilisation yet.
Is Simparica Trio still the market leader?
Yes, with roughly 21% U.S. in-clinic share, nearly double the nearest competitor. But the franchise was flat globally because U.S. declines offset international growth.
What is the long-acting Cytopoint formulation?
A new formulation expected to receive approval later in 2026. It is intended to differentiate Cytopoint from competitors and could become a key tool in the dermatology recovery strategy.
Sources
BigGo Finance — Zoetis Slashes 2026 Outlook After Key Dermatology Sales Tumble 16% and U.S. Companion Animal Plunges 11% (06 August 2026)
Zoetis — Second Quarter 2026 Results (06 August 2026)